Melanoma is the most malignant form of
skin cancer and is associated with a very poor prognosis. The aim of this study was to evaluate the apoptotic effects of
cudraflavone C on A375.S2
melanoma cells and to determine the underlying mechanisms involved in apoptosis. Cell viability was determined using the MTT and real-time cytotoxicity assays. Flow cytometric evaluation of apoptosis was performed after staining the cells with
Annexin V-FITC and
propidium iodide. The mitochondrial membrane potential was evaluated using the
JC-1 assay. Cellular ROS production was measured using the CellROX assay, while mitochondrial ROS production was evaluated using the
MitoSOX assay. It was observed that
cudraflavone C inhibited growth in A375.S2
melanoma cells, and promoted apoptosis via the mitochondrial pathway mediated by increased mitochondrial ROS production. In addition,
cudraflavone C induced phosphorylation of MAPKs (p38, ERK, and JNK) and up-regulated the expression of apoptotic
proteins (Puma, Bax, Bad, Bid, Apaf-1,
cytochrome C,
caspase-9, and
caspase-3/7) in A375.S2 cells. Pretreatment of A375.S2 cells with MitoTEMPOL (a mitochondria-targeted
antioxidant) attenuated the phosphorylation of MAPKs, expression of apoptotic
proteins, and the overall progression of apoptosis. In summary,
cudraflavone C induced apoptosis in A375.S2
melanoma cells by increasing mitochondrial ROS production; thus, activating p38, ERK, and JNK; and increasing the expression of apoptotic
proteins. Therefore,
cudraflavone C may be regarded as a potential form of treatment for
malignant melanoma.